Collectively, our data on RARβ and previous research by others on RARα indicate that RARs are protective against steatosis and could be exploited therapeutically to limit the onset of liver disorders characterized by a dysregulation of lipid metabolism. This evidence concerns the gene RARS1 and liver disorder.